Annual Accounts Receivable
$30.59 M
-$8.00 M-20.74%
31 December 2023
Summary:
AbCellera Biologics annual accounts receivable is currently $30.59 million, with the most recent change of -$8.00 million (-20.74%) on 31 December 2023. During the last 3 years, it has fallen by -$182.65 million (-85.65%). ABCL annual accounts receivable is now -85.65% below its all-time high of $213.24 million, reached on 31 December 2020.ABCL Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$31.37 M
-$4.77 M-13.20%
30 September 2024
Summary:
AbCellera Biologics quarterly accounts receivable is currently $31.37 million, with the most recent change of -$4.77 million (-13.20%) on 30 September 2024. Over the past year, it has dropped by -$6.07 million (-16.22%). ABCL quarterly accounts receivable is now -90.62% below its all-time high of $334.40 million, reached on 31 March 2022.ABCL Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABCL Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -20.7% | -16.2% |
| 3 y3 years | -85.7% | -28.1% |
| 5 y5 years | +5036.0% | - |
ABCL Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -85.7% | at low | -90.6% | +56.8% |
| 5 y | 5 years | -85.7% | +5036.0% | -90.6% | +1377.1% |
| alltime | all time | -85.7% | +5036.0% | -90.6% | +1377.1% |
AbCellera Biologics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $31.37 M(-13.2%) |
| June 2024 | - | $36.14 M(+5.0%) |
| Mar 2024 | - | $34.42 M(+12.5%) |
| Dec 2023 | $30.59 M(-20.7%) | $30.59 M(-18.3%) |
| Sept 2023 | - | $37.45 M(-18.0%) |
| June 2023 | - | $45.68 M(+128.4%) |
| Mar 2023 | - | $20.00 M(-48.2%) |
| Dec 2022 | $38.59 M | $38.59 M(-63.6%) |
| Sept 2022 | - | $105.96 M(+100.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2022 | - | $52.80 M(-84.2%) |
| Mar 2022 | - | $334.40 M(+108.3%) |
| Dec 2021 | $160.58 M(-24.7%) | $160.58 M(+268.0%) |
| Sept 2021 | - | $43.63 M(+1458.9%) |
| June 2021 | - | $2.80 M(-88.0%) |
| Mar 2021 | - | $23.37 M(-89.0%) |
| Dec 2020 | $213.24 M(>+9900.0%) | $213.24 M(+3755.2%) |
| Sept 2020 | - | $5.53 M(+160.4%) |
| Dec 2019 | $2.12 M(+256.6%) | $2.12 M |
| Dec 2018 | $595.60 K | - |
FAQ
- What is AbCellera Biologics annual accounts receivable?
- What is the all time high annual accounts receivable for AbCellera Biologics?
- What is AbCellera Biologics annual accounts receivable year-on-year change?
- What is AbCellera Biologics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for AbCellera Biologics?
- What is AbCellera Biologics quarterly accounts receivable year-on-year change?
What is AbCellera Biologics annual accounts receivable?
The current annual accounts receivable of ABCL is $30.59 M
What is the all time high annual accounts receivable for AbCellera Biologics?
AbCellera Biologics all-time high annual accounts receivable is $213.24 M
What is AbCellera Biologics annual accounts receivable year-on-year change?
Over the past year, ABCL annual accounts receivable has changed by -$8.00 M (-20.74%)
What is AbCellera Biologics quarterly accounts receivable?
The current quarterly accounts receivable of ABCL is $31.37 M
What is the all time high quarterly accounts receivable for AbCellera Biologics?
AbCellera Biologics all-time high quarterly accounts receivable is $334.40 M
What is AbCellera Biologics quarterly accounts receivable year-on-year change?
Over the past year, ABCL quarterly accounts receivable has changed by -$6.07 M (-16.22%)